Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Odyssean extends winning run of bids as Clinigen receives takeover approach

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
A takeover approach for Clinigen (CLIN:AIM) provides another boost for shareholder Odyssean Investment Trust (OIT) and extends the trust’s formidable run of selecting takeover targets.
Having attracted the attentions of activist Elliott, shares in specialist pharmaceutical products and services group Clinigen spiked on news (2 Dec) it is in talks with Triton Investment Management over a possible offer. It becomes the seventh company in Odyssean’s portfolio to receive a bid since November 2019.
Running a concentrated portfolio of smaller companies, Odyssean’s managers Stuart Widdowson and Ed Wielechowski have proven expertise in picking companies that could prove attractive to private equity or strategic trade buyers.
Results for the six months to September 2021 revealed a 13.5% rise in Odyssean’s net asset value per share, exceeding the 9.1% increase for the MSCI ex IT plus AIM Total Return index.
‘More impressively,’ explained chairman Jane Tufnell, ‘this performance has been delivered with an average net cash position in the portfolio of 22%, demonstrating the underlying strength of the performance of the portfolio companies.’
SHARES SAYS: Odyssean Investment Trust remains a buy.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.